Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Cryotherapy kills tumor cells by freezing them. Giving an injection of GM-CSF before cryotherapy and inhaling GM-CSF after cryotherapy may interfere with the growth of tumor cells and shrink the tumor. Giving cryotherapy together with GM-CSF may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving cryotherapy together with GM-CSF works in treating patients with lung metastases or primary lung cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
OBJECTIVES:
Primary
-
Determine whether percutaneous cryotherapy in combination with aerosolized sargramostim (GM-CSF) has any demonstrable immunologic effect in patients with pulmonary metastases or primary lung cancer.
-
Determine whether any systemic immune response is detectable by the combination of cryotherapy as the antigen presentation source and GM-CSF as the immunologic adjuvant.
-
Determine whether low morbidities will be maintained in patients treated with this regimen.
-
Determine whether effective immunization is associated with a drop in CD4+, CD25+, LTP(TGF-β1)+, Tr cells as measured by flow cytometry or ELISPOT assay for TGF-β1-secreting cells.
Secondary
-
Determine clinical response (i.e., tumor control in the dominant masses undergoing cryotherapy or in other metastatic sites) as measured by CT criteria.
-
Determine the toxicity of this regimen in these patients.
OUTLINE: Patients undergo CT-guided core biopsy of a dominant lung mass and placement of at least 2 cryoprobes. Prior to initiating the freeze, patients receive an interstitial injection of sargramostim (GM-CSF) near the tumor. Patients then undergo percutaneous cryotherapy over 2 hours utilizing a freeze-thaw-freeze cycle. Beginning within 3 days of cryotherapy, patients receive aerosolized GM-CSF twice daily for 1 week. Beginning on day 32, patients may elect to undergo a second course of treatment as described above in the absence of disease progression or unacceptable toxicity.
Patients undergo blood and tumor tissue collection at baseline and periodically during study for immunological correlative studies. Peripheral blood mononuclear cells isolated from blood samples are analyzed for antigen-specific CD4-positive or CD8-positive T-cell response by flow cytometry or by TGF-β1 ELISPOT assay to measure TGF-β1- secreting cells. Tumor cell lysates extracted from tumor samples are pulsed with autologous dendritic cells and analyzed by ELISPOT assay to measure T-cell reactivity in tumor specimens.
After completion of study therapy, patients are followed at 6 and 12 months.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Sargramostim, Flow Cytometry, Biopsy. Cryosurgery Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 |
Biological: sargramostim
250 μg, inhaled, two times a day, on days 4-10 and days 36-42
Other Names:
Other: flow cytometry
Days 1 & 32
Other: immunoenzyme technique
Days 1 & 32
Procedure: biopsy
CT guided biopsy on days 1 & 32
Procedure: cryosurgery
Days 1 and 32
|
Outcome Measures
Primary Outcome Measures
- Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry [Days 1 & 32]
CT-guided biopsy & Peritumoral GM-CSF. a CR was defined as involution of the prior tumor and/or ablation site to only a thin, non-enhancing scar within the pulmonary parenchyma on enhanced chest CT. A PR was defined as incomplete resolution of an otherwise thoroughly hypovascular resolving ablation zone which had reached a diameter smaller than the original tumor size. Stable disease (SD) reflects no significant change in size of ablation site and/or overall tumor burden, while the standard definition for progressive disease (PD) remains as evidence of neTw or growing tumors.
Secondary Outcome Measures
- Clinical Response as Measured by CT Criteria [Days 1 & 32]
CT-guided biopsy. a CR was defined as involution of the prior tumor and/or ablation site to only a thin, non-enhancing scar within the pulmonary parenchyma on enhanced chest CT. A PR was defined as incomplete resolution of an otherwise thoroughly hypovascular resolving ablation zone which had reached a diameter smaller than the original tumor size. Stable disease (SD) reflects no significant change in size of ablation site and/or overall tumor burden, while the standard definition for progressive disease (PD) remains as evidence of neTw or growing tumors.
- Toxicity of Grade 1 or Higher [Days 11, 32, 43, & 63]
Number of Participants with Toxicity of Grade 1 or Higher as defined by CTCAE v2
- Immune Function and Cancer-specific Response [Days 1 & 63]
Number of Participants with CT-guided biopsy & Peritumoral GM-CSF. The number of IFNγ secreting T-cells was measured by a direct EliSpots at 10:1 E:T ratio to define the kinetics of the CTL responses from pre-CI to day 63 post CI.
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed diagnosis of 1 of the following:
-
Primary non-small cell lung cancer (NSCLC)
-
Any stage nonoperative NSCLC or patient refuses surgery
-
Any cancer with pulmonary metastatic disease (including renal cell cancer)
-
Stage IV disease (any T, any N, M1)
-
Must have 1-10 pulmonary or mediastinal masses meeting the following criteria:
-
At least 1 mass is appropriate for 2 sessions of core biopsy and cryotherapy with relatively easy access/low risk in nonoperative patients (or those refusing surgery)
-
The two dominant masses are defined as either the largest and/or those that may cause imminent morbidity from continued local progression, thereby potentially benefiting from thoracic cryotherapy alone
-
Optimal tumor size > 1.0 cm
-
Dominant masses up to 6 cm in diameter may be considered if thorough cryotherapy coverage can be anticipated with minimal additional treatment morbidity
-
Measurable disease, defined as tridimensional measurements of up to 6 different pulmonary or mediastinal masses ≥ 0.5 cm by CT scan
-
No active pleural effusion that could be related to respiratory infection or requires further work-up
-
No untreated and/or unstable brain metastases
PATIENT CHARACTERISTICS:
-
Karnofsky performance status 70-100%
-
Life expectancy ≥ 12 weeks
-
Granulocyte count ≥ 1,500/mm³
-
Platelet count ≥ 50,000/mm³
-
INR < 1.5 (i.e., normal PT/PTT)
-
Hemoglobin ≥ 8.0 g/dL
-
Bilirubin ≤ 2 times upper limit of normal (ULN)
-
AST ≤ 3 times ULN
-
Satisfactory pulmonary function test as determined by supervising oncologist, thoracic surgeon, or pulmonologist
-
Not pregnant or lactating
-
Negative pregnancy test
-
Fertile patients must use effective contraception
-
No other active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
-
Inactive history of cancer allowed if the patient has been disease-free for > 2 years
-
No serious medical or psychiatric illnesses that would preclude informed consent or limit survival to < 12 wks
-
No uncontrollable cough or inability to lie flat
-
No New York Heart Association class III or IV heart disease
-
No known immunodeficiency state
-
No uncontrolled infection
-
No uncontrolled coagulopathy or bleeding diathesis
-
No advance directive that would prevent the investigator from treating the participant in the event of a complication occurring during or after the procedure
-
No medical contraindication or potential problem that would preclude protocol compliance
PRIOR CONCURRENT THERAPY:
-
More than 4 weeks since prior biologic therapy
-
More than 4 weeks since prior immunotherapy
-
More than 4 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
-
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
-
More than 4 weeks since prior radiotherapy
-
More than 2 weeks since prior corticosteroids
-
More than 1 week since prior parenteral antibiotics
-
At least 1 week since prior aspirin or aspirin-like medications
-
At least 3 days since prior warfarin, clopidogrel bisulfate, or similar compounds
-
No concurrent GM-CSF other than study drug
-
No concurrent G-CSF
-
No concurrent radiotherapy
-
No concurrent glucocorticosteroids
-
No concurrent parenteral antibiotics
-
No concurrent immunosuppressive agents
-
No concurrent drugs that cause bleeding tendencies
-
No other concurrent biologic therapy, immunotherapy, radiotherapy, or chemotherapy
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | United States | 48201-1379 |
Sponsors and Collaborators
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
Investigators
- Study Chair: Peter J. Littrup, MD, Barbara Ann Karmanos Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- CDR0000559667
- P30CA022453
- WSU-C-2795
- WSU-HIC-050304M1(R)F
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Period Title: Overall Study | |
STARTED | 8 |
COMPLETED | 8 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Overall Participants | 8 |
Age (years) [Median (Full Range) ] | |
Median (Full Range) [years] |
55
|
Sex: Female, Male (Count of Participants) | |
Female |
2
25%
|
Male |
6
75%
|
Region of Enrollment (participants) [Number] | |
United States |
8
100%
|
Outcome Measures
Title | Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry |
---|---|
Description | CT-guided biopsy & Peritumoral GM-CSF. a CR was defined as involution of the prior tumor and/or ablation site to only a thin, non-enhancing scar within the pulmonary parenchyma on enhanced chest CT. A PR was defined as incomplete resolution of an otherwise thoroughly hypovascular resolving ablation zone which had reached a diameter smaller than the original tumor size. Stable disease (SD) reflects no significant change in size of ablation site and/or overall tumor burden, while the standard definition for progressive disease (PD) remains as evidence of neTw or growing tumors. |
Time Frame | Days 1 & 32 |
Outcome Measure Data
Analysis Population Description |
---|
Patients who had metastatic Renal Cell carcinoma |
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Measure Participants | 6 |
Complete Response |
1
12.5%
|
Partial Response |
3
37.5%
|
Progressive Disease |
2
25%
|
Title | Clinical Response as Measured by CT Criteria |
---|---|
Description | CT-guided biopsy. a CR was defined as involution of the prior tumor and/or ablation site to only a thin, non-enhancing scar within the pulmonary parenchyma on enhanced chest CT. A PR was defined as incomplete resolution of an otherwise thoroughly hypovascular resolving ablation zone which had reached a diameter smaller than the original tumor size. Stable disease (SD) reflects no significant change in size of ablation site and/or overall tumor burden, while the standard definition for progressive disease (PD) remains as evidence of neTw or growing tumors. |
Time Frame | Days 1 & 32 |
Outcome Measure Data
Analysis Population Description |
---|
only those with metastatic Renal Cell carcinoma |
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Measure Participants | 6 |
Complete Response |
1
12.5%
|
Partial Response |
3
37.5%
|
Progressive Disease |
2
25%
|
Title | Toxicity of Grade 1 or Higher |
---|---|
Description | Number of Participants with Toxicity of Grade 1 or Higher as defined by CTCAE v2 |
Time Frame | Days 11, 32, 43, & 63 |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Measure Participants | 8 |
Alergic Reaction |
1
12.5%
|
Allergic rhinitis |
2
25%
|
Anemia |
1
12.5%
|
Anorexia |
1
12.5%
|
Atelectasis |
1
12.5%
|
Bronchospasm, wheezing |
1
12.5%
|
Chest Pain (noncardiac, nonpleuritic) |
1
12.5%
|
Chest wall pain |
6
75%
|
Cough |
7
87.5%
|
Decreased platelets |
1
12.5%
|
Dizziness |
1
12.5%
|
Dyspnea |
4
50%
|
Fatigue |
4
50%
|
Hemoptysis |
1
12.5%
|
Hemorrhage, pulmonary lung (hemoptysis) |
4
50%
|
Hyperglycemia |
1
12.5%
|
Low grade fever |
1
12.5%
|
Lymphopenia |
2
25%
|
Nausea |
1
12.5%
|
Pain at incision site |
1
12.5%
|
Pain-upper resp. throat |
2
25%
|
Platelets Low |
1
12.5%
|
Pneumothorax |
4
50%
|
Sensory Neuropathy |
1
12.5%
|
Shortness of Breath |
1
12.5%
|
Sweating |
1
12.5%
|
Thrombocytopenia |
1
12.5%
|
Vomiting |
1
12.5%
|
Title | Immune Function and Cancer-specific Response |
---|---|
Description | Number of Participants with CT-guided biopsy & Peritumoral GM-CSF. The number of IFNγ secreting T-cells was measured by a direct EliSpots at 10:1 E:T ratio to define the kinetics of the CTL responses from pre-CI to day 63 post CI. |
Time Frame | Days 1 & 63 |
Outcome Measure Data
Analysis Population Description |
---|
only those with metastatic Renal Cell carcinoma |
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery |
---|---|
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 |
Measure Participants | 6 |
increase of IFN gamma secreting T cells |
4
50%
|
elevated antibody levels |
4
50%
|
Increased anti-RC-2+KCI-18 serum antibodies |
4
50%
|
Adverse Events
Time Frame | ||
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Sargramostim, Flow Cytometry, Biopsy. Cryosurgery | |
Arm/Group Description | Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32 sargramostim: 250 μg, inhaled, two times a day, on days 4-10 and days 36-42 flow cytometry: Days 1 & 32 immunoenzyme technique: Days 1 & 32 biopsy: CT guided biopsy on days 1 & 32 cryosurgery: Days 1 and 32 | |
All Cause Mortality |
||
Sargramostim, Flow Cytometry, Biopsy. Cryosurgery | ||
Affected / at Risk (%) | # Events | |
Total | / (NaN) | |
Serious Adverse Events |
||
Sargramostim, Flow Cytometry, Biopsy. Cryosurgery | ||
Affected / at Risk (%) | # Events | |
Total | 0/8 (0%) | |
Other (Not Including Serious) Adverse Events |
||
Sargramostim, Flow Cytometry, Biopsy. Cryosurgery | ||
Affected / at Risk (%) | # Events | |
Total | 7/8 (87.5%) | |
Blood and lymphatic system disorders | ||
Anemia | 1/8 (12.5%) | 1 |
Decreased Platelets ( thrombocytopenia) | 1/8 (12.5%) | 1 |
Gastrointestinal disorders | ||
Nausea | 1/8 (12.5%) | 1 |
General disorders | ||
Chest Pain (noncardiac, nonpleuritic) | 1/8 (12.5%) | 1 |
Fatigue | 4/8 (50%) | 4 |
Low grade fever | 1/8 (12.5%) | 1 |
Pain at incision site | 1/8 (12.5%) | 1 |
Immune system disorders | ||
Allergic Reaction | 1/8 (12.5%) | 1 |
Investigations | ||
Lymphopenia (low lever of lymphocytes) | 2/8 (25%) | 2 |
Platelets (low count, thrombocytopenia) | 2/8 (25%) | 2 |
Metabolism and nutrition disorders | ||
Anorexia | 1/8 (12.5%) | 1 |
Hyperglycemia | 1/8 (12.5%) | 1 |
Musculoskeletal and connective tissue disorders | ||
Chest Wall Pain | 6/8 (75%) | 12 |
Nervous system disorders | ||
Dizziness | 1/8 (12.5%) | 1 |
Sensory Neuropathy | 1/8 (12.5%) | 1 |
Respiratory, thoracic and mediastinal disorders | ||
Allergic Rhinitis | 2/8 (25%) | 2 |
Atelectasis | 1/8 (12.5%) | 1 |
Bronchospasm, wheezing | 1/8 (12.5%) | 1 |
Cough | 7/8 (87.5%) | 12 |
Dyspnea | 4/8 (50%) | 5 |
Hemoptysis | 1/8 (12.5%) | 1 |
Hemorrhage, pulmonary lung (hemoptysis) | 4/8 (50%) | 5 |
Pain - Upper Respiratory throat | 2/8 (25%) | 2 |
Pneumothorax | 4/8 (50%) | 6 |
Shortness of Breath | 1/8 (12.5%) | 2 |
Skin and subcutaneous tissue disorders | ||
Sweating | 1/8 (12.5%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Peter Littrup, M.D. |
---|---|
Organization | Barbara Ann Karmanos Cancer Institute |
Phone | 313-576-8758 |
littrupp@karmanos.org |
- CDR0000559667
- P30CA022453
- WSU-C-2795
- WSU-HIC-050304M1(R)F